Recent director dealings and insider transactions at Edwards Lifesciences Corporation (EW),
from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
Date
Insider
Type
Shares
2026-08-31
Dahl Andrew M.
SELL
544
2026-08-28
Bruls Annette
SELL
2,644
2026-08-26
Chopra Daveen
SELL
31,800
2026-08-26
Chopra Daveen
SELL
30,646
2026-08-26
Chopra Daveen
SELL
1,154
2026-08-26
Chopra Daveen
BUY
31,800
2026-08-26
Markowitz Wayne
SELL
1,240
2026-08-11
Lippis Daniel J.
SELL
619
2026-08-11
Lippis Daniel J.
SELL
619
2026-08-11
Lippis Daniel J.
BUY
619
Graham NCAV AnalysisAbove net-net level
Current Assets$6.74B
Less: Total Liabilities−$3.36B
= Net Current Asset Value$3.38B
NCAV Per Share$5.1303
Current Price$89.90
Price / NCAV17.52×
Margin of Safety-1652.3%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
Beta0.852
Dividend/yrNone
52W High$96.29
52W Low$72.30
52-Week Range
$72.30Now$96.29
60% through annual range
From 52W High−9.9%
From 52W Low+19.9%
📖 Plain English Summary
Edwards Lifesciences Corporation is at 60% of its 52-week range. Beta 0.852 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for EW🟢 Bullish⬜ Neutral🔴 Bearish
🤖
DipBuster AI Analysis — EW
Heuristic · balance sheet, insider filings, price data, academic research
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With …